Abstract
UNLABELLED: Before (166)Ho radioembolization, a small batch of the same type of microspheres is administered as a scout dose instead of the conventional (99m)Tc-macroaggregated albumin ((99m)Tc-MAA). The (166)Ho scout dose provides a more accurate and precise lung shunt assessment. However, in contrast to (99m)Tc-MAA, an unintended extrahepatic deposition of this β-emitting scout dose could inflict radiation damage, the extent of which we aimed to quantify in this study.
METHODS: All patients eligible for radioembolization in our institute between January 2011 and March 2014 were reviewed. Of the extrahepatic depositions of (99m)Tc-MAA on SPECT, the amount and volume were measured. These were used to calculate the theoretic absorbed dose in the case a (166)Ho scout dose had been used. The extrahepatic activity was measured as the sum of all voxels of the deposition. Volumes were measured using a threshold technique including all voxels from the maximum voxel intensity up to a certain percentage. The threshold needed to obtain the true volume was studied in a phantom study.
RESULTS: In the phantom study, a threshold of 40% was found to overestimate the volume, with the consequence of underestimating the absorbed dose. Of 160 patients, 32 patients (34 cases) of extrahepatic deposition were identified. The depositions contained a median of 1.3% (range, 0.1%-19.5%) of the administered activity in a median volume of 6.8 mL (range, 1.1-42 mL). The use of a scout dose of 250 MBq of (166)Ho microspheres in these cases would theoretically have resulted in a median absorbed dose of 6.0 Gy (range, 0.9-374 Gy). The dose exceeded a limit of 49 Gy (reported in 2013) in 2 of 34 cases (5.9%; 95% confidence interval, 0.7%-20.1%) or 2 of 160 (1.3%; 95% confidence interval, 0.1%-4.7%) of all patients. In these 2 patients with a large absorbed dose (112 and 374 Gy), the culprit vessel was identified in 1 case.
CONCLUSION: Extrahepatic deposition of a (166)Ho scout dose seems to be theoretically safe in most patients. Its safety in clinical practice is being evaluated in ongoing clinical trials.
| Original language | English |
|---|---|
| Pages (from-to) | 817-23 |
| Number of pages | 7 |
| Journal | Journal of Nuclear Medicine |
| Volume | 56 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jun 2015 |
Keywords
- Adult
- Aged
- Aged, 80 and over
- Biological Markers
- Carcinoma, Hepatocellular
- Cross-Sectional Studies
- Embolization, Therapeutic
- Female
- Holmium
- Humans
- Liver
- Liver Neoplasms
- Lung
- Male
- Microspheres
- Middle Aged
- Phantoms, Imaging
- Radioisotopes
- Retrospective Studies
- Technetium Tc 99m Aggregated Albumin
- Tomography, Emission-Computed, Single-Photon
- Yttrium Radioisotopes